Generated by AI
BioNTech SE American Depositary Share is the U.S.-traded depositary share of BioNTech SE, a Germany-based biotechnology company focused on immunotherapy and vaccines. The company develops cancer therapeutics, including individualized treatment approaches such as personalized immunotherapies, and also works on vaccines for infectious diseases. Its research and development activities span multiple platforms, including mRNA-based products, cell therapies, and other next-generation immune-modulating technologies. BioNTech serves global healthcare and life-science markets through a portfolio centered on oncology and infectious-disease prevention. The American Depositary Share structure allows U.S. investors to trade BioNTech’s ordinary share interest in a familiar market format, while the underlying business remains concentrated on advancing medical research, clinical development, and commercialized biotechnology products.
WebsiteAn der Goldgrube 12
Mainz, 55131
Germany
The latest articles about BNTX.
BioNTech (NasdaqGS:BNTX) is back in focus after Arbutus Biopharma and Genevant expanded their patent enforcement campaign by filing new lawsuits in Japan and updating an existing Canadian case tied to mRNA lipid nanoparticle technology. Investors have watched BioNTech give back ground over 2026, with the share price down 12.05% year to date and the 1 year total shareholder return declining 18.14%. This suggests momentum has been fading even as fresh earnings, updated guidance and buybacks...
Summary of Nov 3's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
Moderna, led by CEO Stéphane Bancel, is forging the future of mRNA with its new personalized cancer vaccine.
Summary of Mar 28's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Investors talking about BNTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.